Telix Pharmaceuticals Ltd (TLX) Latest Filing Signal

Latest Filing: 20-F  |  Filed Feb 20, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Telix Pharmaceuticals Ltd?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, Telix Pharmaceuticals Ltd's filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+18.73%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Telix Pharmaceuticals Ltd actually do?
Answer:
Telix Pharmaceuticals Limited is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for oncology and rare diseases. The company focuses on a 'theranostic' approach, combining diagnostic imaging agents with targeted radionuclide therapies. Telix operates through three reportable segments: Therapeutics (Tx), Precision Medicine (Px), and Manufacturing Solutions (TMS). Its pipeline includes late-stage therapeutic candidates for prostate, kidney, and brain cancers, alongside diagnostic imaging agents for prostate and kidney cancers. The company is expanding its global manufacturing footprint and capabilities to support product delivery worldwide.
Question:
What are Telix Pharmaceuticals Ltd's revenue drivers?
Answer:
Revenue is primarily driven by the commercial sales of its diagnostic imaging agents, Illuccix and Gozellix, within its Precision Medicine segment. The Manufacturing Solutions segment also contributes revenue through contract manufacturing services and sales of PET and SPECT products.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required